Product Images Rivastigmine Tartrate

This text contains dosage, storage, and packaging information for rivastigmine tartrate capsules, including details on where to store the medication, how to package it, and how to dispense it. Additionally, the text provides information on the manufacturer and distributor of the capsules, as well as a unique identifying number (NDC 62756-145-86) for the medication. There is also a batch number and expiration date listed, suggesting that the capsules have a limited shelf life.*

This is a medication called Rivastigmine Tartrate that is distributed by Sun Pharmaceutical Industries. It is sold in capsule form and the usual dosage can be found in the package insert. The medication should be kept out of reach of children and stored at temperatures between 15°C and 30°C. The package contains 60 capsules and is for prescription use only.*

This text provides information regarding the dosage and storage of Rivastigmine Tartrate Capsules, including the recommended temperature range and caution to keep them away from children. The text also includes details such as NDC number, the manufacturer's name, and batch number.*

This text provides dosage and storage information for Rivastigmine Tartrate capsules. The recommended dosage must be obtained from the package insert. It is advised to keep the capsules away from children and store them in a tight container at room temperature. Batch number, NDC, and manufacturer's details are also provided.*

Mean change from baseline in ADAS-cog rating was evaluated in a study involving patients completing 26 weeks of treatment. A time-course of change from baseline in ADAS-cog score is depicted in figure 1, with clinical improvement and decline noted. Dosages of 6-12mg and 1-4mg were used, along with a placebo, during the 26 weeks of treatment.*

The text describes a graph (Figure 2) that shows the cumulative percentage of patients completing 26 weeks of a double-blind study. The graph displays the change from baseline ADAS-cog scores for three treatment groups, including placebo (84% completed), 1-4mg (85% completed), and 6-12mg (65% completed). The X-axis measures the change in ADAS-cog, while the Y-axis shows the cumulative percentage of patients completing treatment.*

The image figure shows the frequency distribution of CIBIC-Plus scores at Week 26 in Study 1. It depicts the percentage of patients who experienced significant improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, or significant worsening based on their CIBIC-Plus rating. The text also includes dosage information for placebo and medication groups.*

This is a figure showing the time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 26 Weeks of Treatment. The graph includes symbols representing clinical improvement, clinical decline, and a placebo group. The x-axis represents time in weeks, and the y-axis represents the mean change from baseline in ADAS-cog rating. No further information is available.*

The figure shows a frequency distribution of CIBIC-Plus scores at week 26 in Study 2, categorized by placebo, 1 to 6 mg, and 6 to 12 mg. The percentage of patients in each category of markedly improved, moderately improved, minimally improved, unchanged, minimally worse, moderately worse, and markedly worse is displayed.*